5-羟色胺2A受体基因T102C多态性与氯氮平疗效个体差异的关联分析

Analysis the relationship between polymorphism in the serotonin 2A receptor gene and variability among individuals in their response to clozapine

目的探讨5-羟色胺2A受体基因T102C多态性与氯氮平疗效个体差异之间的关系.方法81例精神分裂症患者单用氯氮平治疗6～8周,用阳性与阴性症状量表评定氯氮平的疗效,并根据量表的减分率将患者分为有效和无效2组(≥50%,为有效;＜50%,为无效).检测患者的血清氯氮平浓度.用聚合酶链式反应-限制性片段长度多态性技术,检测精神分裂症患者基因型和等位基因的频率.结果5-羟色胺2A受体基因T102C多态性的基因型和等位基因的频率在氯氮平总疗效、改善阳性和阴性症状疗效上,2组间比较无显著性差异.结论氯氮平治疗精神分裂症的总疗效、改善阳性及阴性症状疗效的个体差异与5-羟色胺2A受体基因T102C多态性无关.

Objective To investigate the relationship between T102C polymorphismin the serotonin (5-HT 2A) receptor gene and response to clozapine in schizophrenicpatients. Methods Eighty one patients with schizophrenia were treated by clozapinefor 6~8 weeks. The clinical response was determined by the positive and negativesymptom scale(PANSS). The patients were divided into two groups according tothe reductive rate of score of PANSS ≥50% and <50% , respectively. In order toensure that patients maitain an adequate plasma therapeutic concentration ofclozapine, plasma clozapine levels were monitored during treatment to assesscompliance and exclude confusion raising by variability in clozapine metabolism.The genotype and alleles in these patients were examined with polymerase chainreaction and restriction fragment length polymorphismtechnique. The significancefor the association was estimated by χ2 and t test. Results Genetype and alletefrequences of 5-HT 2A receptor gene T102C polymorphism did not differ significantlybetween response group and non-response group which divided by improvingtotal schizophrenic symptom or positive symptom or negative symptom. Conclusionclozapine response do not associated with 5-HT 2A receptor gene T102Cpolymorphism.